Understanding the journey of a drug within the body – its absorption, distribution, metabolism, and excretion (ADME) – is fundamental to its effective use in therapy. Ombitasvir (Abt-267), a vital NS5A inhibitor for Hepatitis C Virus (HCV) treatment, possesses a distinct pharmacokinetic profile and metabolic pathway that are crucial for its therapeutic success. This article explores these aspects, highlighting the importance of quality pharmaceutical intermediates like Ombitasvir supplied by NINGBO INNO PHARMCHEM CO.,LTD.

Upon oral administration, Ombitasvir exhibits an absolute bioavailability of approximately 48%. It reaches peak plasma concentrations around 5 hours after ingestion. The exposure to Ombitasvir can be influenced by food intake; consumption with high or normal fat meals leads to a notable increase in its exposure, factors that are considered during treatment regimens. This understanding of absorption is key to optimizing dosage and effectiveness, particularly when Ombitasvir is part of a combination therapy.

The distribution of Ombitasvir is characterized by a steady-state volume of distribution of 173 liters, suggesting it distributes into body tissues. While its clearance rate has not been precisely determined, its elimination primarily occurs through the feces, accounting for about 90.2% of the administered dose, with only a small fraction excreted in the urine (1.91%). The parent compound constitutes the majority of the excreted material, indicating limited extensive first-pass metabolism or rapid conversion into other forms before elimination.

Ombitasvir undergoes metabolism primarily through amide hydrolysis, followed by oxidative metabolism mediated by the cytochrome P450 enzyme CYP2C8. Understanding these metabolic pathways is important for identifying potential drug-drug interactions with other medications metabolized by the same enzymes. The biological half-life of Ombitasvir ranges from 21 to 25 hours, which is consistent with its dosing frequency in combination therapies for HCV.

For researchers and pharmaceutical manufacturers, accessing high-quality Ombitasvir is essential for advancing HCV treatment. NINGBO INNO PHARMCHEM CO.,LTD. offers Ombitasvir as a reliable pharmaceutical intermediate, supporting critical research into its pharmacokinetic properties and metabolic fate. Such detailed knowledge ensures the safety and efficacy of the final therapeutic products.

In essence, the pharmacokinetic profile and metabolism of Ombitasvir (Abt-267) are critical determinants of its therapeutic efficacy against HCV. Its absorption characteristics, distribution patterns, and metabolic pathways, primarily involving CYP2C8, inform its use in clinical practice. The consistent availability of this crucial intermediate from NINGBO INNO PHARMCHEM CO.,LTD. underpins ongoing efforts to combat Hepatitis C.